These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11193886)

  • 21. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
    Pommier Y
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):3-10. PubMed ID: 8633251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
    Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M
    Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
    Streltsov SA
    J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.
    Bom D; Curran DP; Zhang J; Zimmer SG; Bevins R; Kruszewski S; Howe JN; Bingcang A; Latus LJ; Burke TG
    J Control Release; 2001 Jul; 74(1-3):325-33. PubMed ID: 11489514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.
    Hertzberg RP; Caranfa MJ; Holden KG; Jakas DR; Gallagher G; Mattern MR; Mong SM; Bartus JO; Johnson RK; Kingsbury WD
    J Med Chem; 1989 Mar; 32(3):715-20. PubMed ID: 2537428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical applications of the camptothecins.
    Takimoto CH; Wright J; Arbuck SG
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of novel water-soluble 7-(aminoacylhydrazono)-formyl camptothecins with potent inhibition of DNA topoisomerase I.
    Wang HK; Liu SY; Hwang KM; Taylor G; Lee KH
    Bioorg Med Chem; 1994 Dec; 2(12):1397-402. PubMed ID: 7788302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status and perspectives in the development of camptothecins.
    Zunino F; Dallavalleb S; Laccabuea D; Berettaa G; Merlinib L; Pratesi G
    Curr Pharm Des; 2002; 8(27):2505-20. PubMed ID: 12369944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Camptothecin. Discovery to clinic.
    Wall ME; Wani MC
    Ann N Y Acad Sci; 1996 Dec; 803():1-12. PubMed ID: 8993495
    [No Abstract]   [Full Text] [Related]  

  • 31. The long story of camptothecin: From traditional medicine to drugs.
    Martino E; Della Volpe S; Terribile E; Benetti E; Sakaj M; Centamore A; Sala A; Collina S
    Bioorg Med Chem Lett; 2017 Feb; 27(4):701-707. PubMed ID: 28073672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical and clinical development of camptothecins.
    Costin D; Potmesil M
    Adv Pharmacol; 1994; 29B():51-72. PubMed ID: 8996601
    [No Abstract]   [Full Text] [Related]  

  • 33. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
    Besterman JM
    Ann N Y Acad Sci; 1996 Dec; 803():202-9. PubMed ID: 8993513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.
    Fan Y; Shi LM; Kohn KW; Pommier Y; Weinstein JN
    J Med Chem; 2001 Sep; 44(20):3254-63. PubMed ID: 11563924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silicon-containing analogs of camptothecin as anticancer agents.
    Lazareva NF; Baryshok VP; Lazarev IM
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29239010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy.
    Cragg GM; Newman DJ
    J Nat Prod; 2004 Feb; 67(2):232-44. PubMed ID: 14987065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Camptothecins: new enthusiasm for an old drug.
    Rowe PM
    Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
    [No Abstract]   [Full Text] [Related]  

  • 40. Topoisomerase-I inhibitors in gynecologic tumors.
    Haluska P; Rubin E; Verschraegen CF
    Hematol Oncol Clin North Am; 1999 Feb; 13(1):43-61, vii-viii. PubMed ID: 10080069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.